Stendra (Vivus Inc.) success in rapid Erectile Dysfunction effect in TA 501 trial
Vivus Inc., announced positive results from a multicenter, placebo-controlled study, TA-501, designed to assess the efficacy of Stendra (avanafil) in approximately 15 minutes. In the study, Stendra patients achieved statistically significant improvement over placebo, in the mean proportion of attempts that resulted in erections sufficient for successful intercourse, as early as 10 minutes for the 200 mg dose and 12 minutes for the 100 mg dose after being taken.
Stendra is FDA approved but not yet launched in the USA and CHMP recommended as Spedra in the EU.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins